Login Register Cart 0
Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Clinical Trial

Bumetanide, a Diuretic That Can Help Children with Autism Spectrum Disorder

Author(s): Esraa Shaker, Osama El Agami and Abeer Salamah*

Volume 23, Issue 4, 2024

Published on: 06 June, 2023

Page: [536 - 542] Pages: 7

DOI: 10.2174/1871527322666230404114911

Price: $65

Abstract

Background: Autism Spectrum Disorder (ASD) is a common child neurodevelopmental disorder, whose pathogenesis is not completely understood. Until now, there is no proven treatment for the core symptoms of ASD. However, some evidence indicates a crucial link between this disorder and GABAergic signals which are altered in ASD. Bumetanide is a diuretic that reduces chloride, shifts gamma-amino-butyric acid (GABA) from excitation to inhibition, and may play a significant role in the treatment of ASD.

Objective: The objective of this study is to assess the safety and efficacy of bumetanide as a treatment for ASD.

Methods: Eighty children, aged 3-12 years, with ASD diagnosed by Childhood Autism Rating Scale (CARS), ⩾ 30 were included in this double-blind, randomized, and controlled study. Group 1 received Bumetanide, Group 2 received a placebo for 6 months. Follow-up by CARS rating scale was performed before and after 1, 3, and 6 months of treatment.

Results: The use of bumetanide in group 1 improved the core symptoms of ASD in a shorter time with minimal and tolerable adverse effects. There was a statistically significant decrease in CARS and most of its fifteen items in group 1 versus group 2 after 6 months of treatment (p-value <0.001).

Conclusion: Bumetanide has an important role in the treatment of core symptoms of ASD.

Keywords: ASD (autism spectrum disorder), CARS (childhood autism rating scale), GABA (Gamma-amino-butyric acid), bumetanide, CCC (Cation-chloride Cotransporters), NKCC1, FDA.

« Previous
Graphical Abstract

[1]
Diagnostic and statistical manual of mental disorders. Am Psychiatric Assoc 2013; 21(21): 591-643.
[2]
Weintraub K. The prevalence puzzle: Autism counts. Nature 2011; 479(7371): 22-4.
[http://dx.doi.org/10.1038/479022a] [PMID: 22051656]
[3]
Vivanti G, Kasari C, Green J, Mandell D, Maye M, Hudry K. Implementing and evaluating early intervention for children with autism: Where are the gaps and what should we do? Autism Res 2018; 11(1)
[4]
Cellot G, Cherubini E. GABAergic signaling as therapeutic target for autism spectrum disorders. Front Pediatr 2014; 2: 70.
[http://dx.doi.org/10.3389/fped.2014.00070] [PMID: 25072038]
[5]
Dhossche D, Applegate H, Abraham A, et al. Elevated plasma gamma-aminobutyric acid (GABA) levels in autistic youngsters: Stimulus for a GABA hypothesis of autism. Med Sci Monit 2002; 8(8): 1-6.
[6]
Cohen M. Pharmacology of Bumetanide. J Clin Pharmacol 1981; 21(11): 537-42.
[http://dx.doi.org/10.1002/j.1552-4604.1981.tb05662.x] [PMID: 7338563]
[7]
Delpire E, Mount DB. Human and murine phenotypes associated with defects in cation-chloride cotransport. Annu Rev Physiol 2002; 64(1): 803-43.
[http://dx.doi.org/10.1146/annurev.physiol.64.081501.155847] [PMID: 11826289]
[8]
Zhang S, Zhou J, Zhang Y, et al. The structural basis of function and regulation of neuronal cotransporters NKCC1 and KCC2. Commun Biol 2021; 4(1): 226.
[http://dx.doi.org/10.1038/s42003-021-01750-w] [PMID: 33597714]
[9]
Feng JY, Li HH, Wang B, Shan L, Jia FY. Successive clinical application of vitamin D and bumetanide in children with autism spectrum disorder. Medicine 2020; 99(2): e18661.
[http://dx.doi.org/10.1097/MD.0000000000018661] [PMID: 31914053]
[10]
Lemonnier E, Ben-Ari Y. The diuretic bumetanide decreases autistic behaviour in five infants treated during 3 months with no side effects. Acta Paediatr 2010; 99(12): 1885-8.
[http://dx.doi.org/10.1111/j.1651-2227.2010.01933.x] [PMID: 20608900]
[11]
Li Q, Zhang L, Shan H, Yu J, Dai Y, He H. The immunobehavioural covariation associated with the treatment response to bumetanide in young children with autism spectrum disorder. Transl Psychiatry 2022; 12(1): 228.
[http://dx.doi.org/10.1038/s41398-022-01987-x]
[12]
Moulton E, Bradbury K, Barton M. Factor analysis of the childhood autism rating scale in a sample of two year olds with an autism spectrum disorder. J Autism Dev Disord 2019; 49: 2733-46.
[13]
Kharod SC, Kang SK, Kadam SD. Off-label use of bumetanide for brain disorders: An overview. Front Neurosci 2019; 13: 310.
[http://dx.doi.org/10.3389/fnins.2019.00310] [PMID: 31068771]
[14]
Lemonnier E, Villeneuve N, Sonie S, et al. Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders. Transl Psychiatry 2017; 7(3): e1056.
[http://dx.doi.org/10.1038/tp.2017.10] [PMID: 28291262]
[15]
Gillberg C, Fernell E. Autism plus versus autism pure. J Autism Dev Disord 2014; 44(12): 3274-6.
[http://dx.doi.org/10.1007/s10803-014-2163-1] [PMID: 24958434]
[16]
Bradstreet JJ, Smith S, Granpeesheh D, El-Dahr JM, Rossignol D. Spironolactone might be a desirable immunologic and hormonal intervention in autism spectrum disorders. Med Hypotheses 2007; 68(5): 979-87.
[http://dx.doi.org/10.1016/j.mehy.2006.10.015] [PMID: 17150311]
[17]
Geier DA, Geier MR. A clinical trial of combined anti-androgen and anti-heavy metal therapy in autistic disorders. Neuroendocrinol Lett 2006; 27(6): 833-8.
[PMID: 17187010]
[18]
Guastella AJ, Einfeld SL, Gray KM, et al. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry 2010; 67(7): 692-4.
[http://dx.doi.org/10.1016/j.biopsych.2009.09.020] [PMID: 19897177]
[19]
Rossignol DA. Novel and emerging treatments for autism spectrum disorders: a systematic review. Ann Clin Psychiatry 2009; 21(4): 213-36.
[PMID: 19917212]
[20]
Naviaux RK, Curtis B, Li K, et al. Low-dose suramin in autism spectrum disorder: A small, phase I/II, randomized clinical trial. Ann Clin Transl Neurol 2017; 4(7): 491-505.
[http://dx.doi.org/10.1002/acn3.424] [PMID: 28695149]
[21]
Hajri M, Ben Amor A, Abbes Z, et al. Bumetanide in the management of autism. Tunisian experience in Razi Hospital. Tunis Med 2019; 97(8-9): 971-7.
[PMID: 32173844]
[22]
Lemonnier E, Degrez C, Phelep M, et al. A randomised controlled trial of bumetanide in the treatment of autism in children. Transl Psychiatry 2012; 2(12): e202.
[http://dx.doi.org/10.1038/tp.2012.124] [PMID: 23233021]
[23]
Du L, Shan L, Wang B, et al. A pilot study on the combination of applied behavior analysis and bumetanide treatment for children with autism. J Child Adolesc Psychopharmacol 2015; 25(7): 585-8.
[http://dx.doi.org/10.1089/cap.2015.0045]
[24]
Zhang L, Huang CC, Dai Y, et al. Symptom improvement in children with autism spectrum disorder following bumetanide administration is associated with decreased GABA/glutamate ratios. Transl Psychiatry 2020; 10(1): 9.
[http://dx.doi.org/10.1038/s41398-020-0692-2] [PMID: 32066666]
[25]
Fernell E, Gustafsson P, Gillberg C. Bumetanide for autism: Openlabel trial in six children. Acta Paediatr 2021; 110(5): 1548-53.
[http://dx.doi.org/10.1111/apa.15723] [PMID: 33336381]
[26]
Sprengers JJ, van Andel DM, Zuithoff NPA, et al. Bumetanide for Core Symptoms of Autism Spectrum Disorder (BAMBI): A single center, double-blinded, participant-randomized, placebocontrolled, phase-2 superiority trial. J Am Acad Child Adolesc Psychiatry 2021; 60(7): 865-76.
[http://dx.doi.org/10.1016/j.jaac.2020.07.888] [PMID: 32730977]
[27]
Hadjikhani N, Zürcher NR, Rogier O, et al. Improving emotional face perception in autism with diuretic bumetanide: A proof-ofconcept behavioral and functional brain imaging pilot study. Autism 2015; 19(2): 149-57.
[http://dx.doi.org/10.1177/1362361313514141] [PMID: 24343334]

Rights & Permissions Print Cite
Article Metrics
34
2
© 2024 Bentham Science Publishers | Privacy Policy